Key result
Serotonergic antidepressant use in patients with CF-LVADs was associated with an increased risk of first bleeding events compared to non-use.
Why the study?
This study sought to determine whether serotonergic antidepressant use is associated with bleeding in patients receiving CF-LVAD support.
Does serotonergic antidepressant use increase the risk of bleeding in adult patients receiving continuous-flow left ventricular assist device support?
Cohort (n=594)
No
Does serotonergic antidepressant use increase the risk of bleeding in adult patients receiving continuous-flow left ventricular assist device support?
Serotonergic antidepressant use is associated with a significantly increased risk of bleeding, primarily gastrointestinal, in patients supported with continuous-flow left ventricular assist devices.
Answers are grounded in this paper and cite their sources.
SA use may increase bleeding risk on CF-LVAD support; hypothesis-generating and requires prospective confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Robinson et al. (2021) conducted a cohort in Continuous-flow left ventricular assist device (CF-LVAD) support (n=594). Serotonergic antidepressants vs. No serotonergic antidepressants was evaluated on Incidence of first bleeding events including gastrointestinal bleed (GIB), epistaxis, or intracerebral hemorrhage (ICH) (adjusted OR 1.75, 95% CI 1.22-2.51, p=0.002). Serotonergic antidepressant use in patients with CF-LVADs was associated with an increased risk of first bleeding events compared to non-use.
Synapse has enriched 10 related papers. Consider them for comparative context: